FILING ANALYSIS · THURSDAY, OCTOBER 1
Lantern Pharma Inc. LTRN — 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
neutral
The filing appears to be a routine 8-K submission with no quantified surprises or material disclosures that could impact the stock price.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →